Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE versus PROKLAR.
ILOSONE vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin (ILOSONE) binds to the 50S subunit of bacterial ribosomes, inhibiting peptide chain elongation and protein synthesis by blocking translocation.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Erythromycin (Ilosone) base or stearate: 250-500 mg orally every 6 hours. Estolate: 250-500 mg orally every 6 hours. Maximum dose 4 g/day.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
1.5-2 hours in adults; prolonged in hepatic impairment (up to 5-6 hours)
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Renal (2-5% unchanged), biliary/fecal (majority, >90% as metabolites and unchanged drug)
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic